首页>
外国专利>
COMBINATION THERAPY OF LOWER URINARY TRACT DISORDERS WITH α2δ LIGANDS AND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDs)
COMBINATION THERAPY OF LOWER URINARY TRACT DISORDERS WITH α2δ LIGANDS AND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDs)
展开▼
机译:下排尿道疾病与α 2 Sub>δ配体和非甾体类抗炎药(NSAIDs)联合治疗
展开▼
页面导航
摘要
著录项
相似文献
摘要
The present invention relates to the use of a α2δ calcium channel subunit ligand and of a non-steroidal anti-inflammatory drug in a combination treatment of a lower urinary tract disorder and the non-steroidal anti-inflammatory drug. The subject of the present invention is the use of the α2δ calcium channel subunit (A2d) ligand selected from gabapentin or pregabalin, (1R,5R,6S)-6-aminomethyl-6-carboxymethylbicyclo[3.2.0]heptane, 3-(1-aminomethylcyclohexylmethyl)-4H-1,2,4- oxadiazol-5-one, 5-(1-aminomethylcyclohexylmethyl)-1H-tetrazole, (3S,4S)-(1-aminomethyl-1-carboxymethyl-3,4-dimethylcyclopentane, (1α,3α,5α)-(3-aminomethyl-3-carboxymethylbicyclo[3.2.0]heptane, (3S,5R)-3-aminomethyl-5-methyloctanoic acid, (3S,5R)-3-amino-5-methylheptanoic acid, (3S,5R)-3-amino-5-methyloctanoic acid, (3S,5R)-3-amino-5-methylnonanoic acid, (2S,4S)-4-(3-chlorophenoxy)proline or (2S,4S)-4-(3-fluorobenzyl)proline, or a mixture of two or more thereof in the treatment of urinary incontinence in a subject suffering from a lower urinary tract disorder in combination with the prior, concurrent or post-administration of a non-steroidal anti-inflammatory drug (NSAID). Another subject of the invention is the use of the non-steroidal anti-inflammatory drug in the treatment of urinary incontinence in a subject suffering from a lower urinary tract disorder in combination with the prior, concurrent or post-administration of the α2δ calcium channel subunit (A2d) ligand selected from gabapentin or pregabalin, (1R,5R,6S)-6-aminomethyl-6-carboxymethylbicyclo[3.2.0]heptane, 3-(1-aminomethylcyclohexylmethyl)-4H-1,2,4-oxadiazol-5-one, 5-(1-aminomethylcyclohexylmethyl)-1H-tetrazole, (3S,4S)-(1-aminomethyl-1-carboxymethyl-3,4-dimethylcyclopentane, (1α,3α,5α)-(3-aminomethyl-3-carboxymethylbicyclo[3.2.0]heptane, (3S,5R)-3-aminomethyl-5-methyloctanoic acid, (3S,5R)-3-amino-5-methylheptanoic acid, (3S,5R)-3-amino-5-methyloctanoic acid, (3S,5R)-3-amino-5-methylnonanoic acid, (2S,4S)-4-(3-chlorophenoxy)proline or (2S,4S)-4-(3-fluorobenzyl)proline, or a mixture of two or more thereof. Preferably the non-steroidal anti-inflammatory drug is a COX-inhibitor. It is also preferable that the non-steroidal anti-inflammatory drug is celecoxib, diclofenac, diflunisal, flurbiprofen, naproxen, nimesulide or sulindac. One more subject of the invention is the use of compbination of at least one α2δ calcium channel subunit (A2d) ligand and at least one non-steroidal anti-inflammatory drug for the concurrent or post-administration in the treatment of urinary incontinence in a subject suffering from a lower urinary tract disorder. Another subject of the invention is the use of the α2δ calcium channel subunit (A2d) ligand for the preparation of a medicament for the treatment of urinary incontinence in a subject suffering from a lower urinary tract disorder in combination with the prior, concurrent or post-administration of a non-steroidal anti-inflammatory drug (NSAID). One more subject of the invention is the use of the non-steroidal anti-inflammatory drug for the preparation of a medicament for the treatment of urinary incontinence in a subject suffering from a lower urinary tract disorder in combination with the prior, concurrent or post-administration of the α2δ calcium channel subunit (A2d) ligand.
展开▼